NVS Quote, Financials, Valuation and Earnings

Monte Rosa Therapeutics, Inc. has a net margin of 28.26% compared to Novartis AG's net margin of -212.1%. Novartis AG's return on equity of 33.87% beat Monte Rosa Therapeutics, Inc.'s return on equity of 8.6%.

Novartis AG has a consensus price target of $134.88, signalling upside risk potential of 0.87%. On the other hand Monte Rosa Therapeutics, Inc. has an analysts' consensus of $17.20 which suggests that it could grow by 2.02%. Given that Monte Rosa Therapeutics, Inc. has higher upside potential than Novartis AG, analysts believe Monte Rosa Therapeutics, Inc. is more attractive than Novartis AG.

Novartis AG has a beta of 0.525, which suggesting that the stock is 47.542% less volatile than S&P 500. In comparison Monte Rosa Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.99%. Monte Rosa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 55.39% of its earnings as a dividend. Monte Rosa Therapeutics, Inc. pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.9B, which are larger than Monte Rosa Therapeutics, Inc. quarterly revenues of $12.8M. Novartis AG's net income of $3.9B is higher than Monte Rosa Therapeutics, Inc.'s net income of -$27.1M. Notably, Novartis AG's price-to-earnings ratio is 18.24x while Monte Rosa Therapeutics, Inc.'s PE ratio is 55.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.84x versus 7.18x for Monte Rosa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 28.26% compared to Novartis AG's net margin of 38.89%. Novartis AG's return on equity of 33.87% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Novartis AG has a consensus price target of $134.88, signalling upside risk potential of 0.87%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $768.36 which suggests that it could grow by 6.18%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Novartis AG, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Novartis AG.

Novartis AG has a beta of 0.525, which suggesting that the stock is 47.542% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.99%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Novartis AG pays 55.39% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.9B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Novartis AG's net income of $3.9B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Novartis AG's price-to-earnings ratio is 18.24x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.84x versus 5.60x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 28.26% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 33.87% beat Roche Holding AG's return on equity of 28.65%.

Novartis AG has a consensus price target of $134.88, signalling upside risk potential of 0.87%. On the other hand Roche Holding AG has an analysts' consensus of $51.13 which suggests that it could grow by 4.52%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.525, which suggesting that the stock is 47.542% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.97%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.99%. Roche Holding AG offers a yield of 2.84% to investors and pays a quarterly dividend of $1.39 per share. Novartis AG pays 55.39% of its earnings as a dividend. Roche Holding AG pays out 58.07% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.9B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $3.9B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 18.24x while Roche Holding AG's PE ratio is 28.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.84x versus 4.42x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.

Avidity Biosciences, Inc. has a net margin of 28.26% compared to Novartis AG's net margin of -1398.33%. Novartis AG's return on equity of 33.87% beat Avidity Biosciences, Inc.'s return on equity of -37.47%.

Novartis AG has a consensus price target of $134.88, signalling upside risk potential of 0.87%. On the other hand Avidity Biosciences, Inc. has an analysts' consensus of $74.00 which suggests that it could grow by 3.38%. Given that Avidity Biosciences, Inc. has higher upside potential than Novartis AG, analysts believe Avidity Biosciences, Inc. is more attractive than Novartis AG.

Novartis AG has a beta of 0.525, which suggesting that the stock is 47.542% less volatile than S&P 500. In comparison Avidity Biosciences, Inc. has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.581%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.99%. Avidity Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 55.39% of its earnings as a dividend. Avidity Biosciences, Inc. pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.9B, which are larger than Avidity Biosciences, Inc. quarterly revenues of $12.5M. Novartis AG's net income of $3.9B is higher than Avidity Biosciences, Inc.'s net income of -$174.4M. Notably, Novartis AG's price-to-earnings ratio is 18.24x while Avidity Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.84x versus 450.42x for Avidity Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.